Immix Biopharma (IMMX) Cash from Financing Activities (2021 - 2026)

Immix Biopharma has disclosed Cash from Financing Activities across 6 years of filings, most recently posting -$37561.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$37561.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $106.2 million (changed N/A YoY), and the FY2025 annual result was $107.4 million, up 573.33% from the prior year.
• Cash from Financing Activities came in at -$37561.0 for Q1 2026 at Immix Biopharma, down from $95.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $95.7 million in Q4 2025 to a low of -$105963.0 in Q2 2022.
• The 5-year median for Cash from Financing Activities is $2.9 million (2022), against an average of $12.8 million.
• Across the five-year window, Cash from Financing Activities sank 228.71% in 2022 and surged 13311.62% in 2024, its largest moves.
• Immix Biopharma's Cash from Financing Activities stood at $424276.0 in 2022, then soared by 38.28% to $586692.0 in 2023, then jumped by 2618.39% to $15.9 million in 2024, then jumped by 499.86% to $95.7 million in 2025, then slumped by 100.04% to -$37561.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$37561.0 (Q1 2026), $95.7 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.